Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 408 across all filing types
Latest filing 2021-08-17 Interim / Quarterly Rep…
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half-year Report' and 'Interim Report for the six months ended 30 June 2021'. It contains detailed financial highlights, operational reviews, and financial statements (Revenue, Cost of sales, Balance sheet, etc.) for the specified interim period. It is not a mere announcement of a report, as it provides the full content of the interim results. Therefore, it is classified as an Interim/Quarterly Report. H1 2021
2021-08-17 English
Licence agreement secured in Republic of Korea
M&A Activity Classification · 99% confidence The document begins with an 'RNS Number' and is dated August 12, 2021. It announces a significant corporate event: an exclusive licence agreement secured in the Republic of Korea for the product Accrufer®. The text details financial terms (upfront payment, milestones, royalties) and strategic partnership information. This type of announcement, which is a formal notification of a material event to the market, is characteristic of a regulatory news service release. Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a dividend notice (DIV), and it is clearly a general market announcement distributed via RNS, the most appropriate classification is Regulatory Filings (RNS). The document length (7578 chars) is substantial enough that it is the primary announcement itself, not just a brief notice pointing to an attachment (which would suggest RPA).
2021-08-12 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is a short announcement (3555 characters) released via RNS (London Stock Exchange news service). The title is "Notice of Results" and the content explicitly states that the company "will announce its interim results for the six months ended 30 June 2021 on Tuesday 17 August 2021." This structure—announcing the future publication date and details of an upcoming report (Interim Results)—fits the definition of a Report Publication Announcement (RPA). It is not the Interim Report (IR) itself, nor is it a general regulatory filing (RNS) since a more specific category (RPA) applies based on the 'Menu vs Meal' rule.
2021-08-11 English
AEGIS-CKD study results published in AJKD
Regulatory Filings Classification · 99% confidence The document starts with an 'RNS Number' and is dated August 9, 2021. It is a short announcement from Shield Therapeutics plc regarding the publication of positive study results for their product in the American Journal of Kidney Disease. The text explicitly states, 'This information is provided by Reach, the non-regulatory press release distribution service of RNS...' and later, 'Reach is a non-regulatory news service.' This indicates it is a general press release distributed via the RNS platform, but it is not a formal regulatory filing like a 10-K, IR, or ER. Since it is a general announcement that doesn't fit the specific categories (like DIV, DIRS, MANG, etc.), the most appropriate fallback category is Regulatory Filings (RNS), which serves as the general category for miscellaneous announcements distributed through the RNS system, even if explicitly marked as non-regulatory Reach content.
2021-08-09 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1939 characters) and contains the header 'RNS Number : 6116H' and explicitly mentions 'This information is provided by RNS, the news service of the London Stock Exchange.' The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific, time-sensitive market announcement. Since it is a general regulatory announcement disseminated via the RNS system and does not fit into the more specific categories like DIV, ER, or DIRS, it falls best under the general Regulatory Filings category (RNS) or potentially a specific trading/market notice if one existed. Given the provided definitions, RNS is the most appropriate fallback for miscellaneous regulatory news releases from the LSE.
2021-08-04 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1922 characters) and contains the header 'RNS Number : 6106H' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Price Monitoring Extension' for a security, which is a specific, brief operational announcement related to trading mechanics, not a comprehensive financial report or a standard corporate action like a dividend or director dealing. Since it is a general regulatory announcement disseminated via the RNS system that doesn't fit into the more specific categories (like 10-K, ER, DIV, etc.), the most appropriate classification is the general Regulatory Filings fallback category.
2021-08-04 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.